ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
azithromycin
Sponsored by
About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Chlamydia pneumoniae, Chlamydophila pneumoniae, Azithromycin
Eligibility Criteria
Inclusion Criteria: adults with stable persistent asthma and evidence for reversible airway obstruction Exclusion Criteria: macrolide allergy, pregnancy or lactation, specified comorbidities or medications
Sites / Locations
Outcomes
Primary Outcome Measures
None specified (pilot study)
Clinical outcomes measured: asthma symptoms, medication use, asthma-specific qulaity-of-life
Serological measures: Chlamydia pneumonaie IgG, IgA by ELISA at baseline and follow up
Secondary Outcome Measures
Full Information
NCT ID
NCT00245908
First Posted
October 27, 2005
Last Updated
October 27, 2005
Sponsor
Wisconsin Research Network
1. Study Identification
Unique Protocol Identification Number
NCT00245908
Brief Title
ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2002
Overall Recruitment Status
Completed
Study Start Date
September 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2002 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Wisconsin Research Network
4. Oversight
5. Study Description
Brief Summary
The ASTHMA Pilot Study is a randomized, controlled, parallel group clinical trial of 6 weekly doses of azithromycin (cumulative dose 4800 mg) or placebo as adjunctive treatment in addition to usual care for adults with stable persistent asthma, with final follow up at 3 months after completion of study medication.
The hypothesis to be tested is that antibiotic treatment will improve asthma at followup, and that this improvement will be limited to patients with evidence of C. pneumoniae infection.
The secondary hypothesis is that randomized, controlled treatment trials can be carried out successfully in a geographically dispersed practice-based research network.
Detailed Description
Asthma is a chronic inflammatory bronchial condition of unknown etiology. Decades ago many clinicians believed that infection played a major role in asthma etiology, but current expert opinion favors the view that asthma is a noninfectious condition whose root cause is inflammation. Therefore chronic antiinflammatory therapy, mainly inhaled corticosteroids, is currently advocated as primary anti-asthma treatment. It is important to recognize, however, that antiinflammatory therapy is palliative, not curative.
A growing body of evidence implicates chronic bronchial infection with Chlamydia pneumoniae in the pathogenesis of asthma in both adults and children. Organism identification studies (culture and PCR) suggest that up to one-half of children with asthma may be chronically infected by C. pneumoniae, and seroepidemiologic studies in adults are consistent with chronic C. pneumoniae infection in the majority of adult-onset asthmatics. Furthermore, case reports and uncontrolled trials have provided provocative but inconclusive evidence that treatment of C. pneumoniae infection in both children and adults with asthma can favorably affect the natural history of this disorder.
We propose a randomized, placebo-controlled, triple-blinded study of antichlamydial antimicrobial therapy in adult-onset asthma. Results will help to determine whether antimicrobial therapy is effective in treating some adult asthma syndromes. Positive results would have significant public health implications. Methodologies developed for use in this trial may expedite future studies in practice-based research networks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Chlamydia pneumoniae, Chlamydophila pneumoniae, Azithromycin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
100 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
azithromycin
Primary Outcome Measure Information:
Title
None specified (pilot study)
Title
Clinical outcomes measured: asthma symptoms, medication use, asthma-specific qulaity-of-life
Title
Serological measures: Chlamydia pneumonaie IgG, IgA by ELISA at baseline and follow up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adults with stable persistent asthma and evidence for reversible airway obstruction
Exclusion Criteria:
macrolide allergy, pregnancy or lactation, specified comorbidities or medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David L Hahn, MD, MS
Organizational Affiliation
Wisconsin Research Network
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
15226283
Citation
Hahn DL, Plane MB. Feasibility of a practical clinical trial for asthma conducted in primary care. J Am Board Fam Pract. 2004 May-Jun;17(3):190-5. doi: 10.3122/jabfm.17.3.190.
Results Reference
background
Learn more about this trial
ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study
We'll reach out to this number within 24 hrs